ECSP066477A - Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo - Google Patents
Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activoInfo
- Publication number
- ECSP066477A ECSP066477A EC2006006477A ECSP066477A ECSP066477A EC SP066477 A ECSP066477 A EC SP066477A EC 2006006477 A EC2006006477 A EC 2006006477A EC SP066477 A ECSP066477 A EC SP066477A EC SP066477 A ECSP066477 A EC SP066477A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical composition
- propyloctanoic
- active ingredient
- includes acid
- present
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 239000007788 liquid Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- YCYMCMYLORLIJX-SNVBAGLBSA-N (2r)-2-propyloctanoic acid Chemical compound CCCCCC[C@H](C(O)=O)CCC YCYMCMYLORLIJX-SNVBAGLBSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229910052728 basic metal Inorganic materials 0.000 abstract 1
- -1 basic metal ion Chemical class 0.000 abstract 1
- 238000010790 dilution Methods 0.000 abstract 1
- 239000012895 dilution Substances 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 229910000000 metal hydroxide Inorganic materials 0.000 abstract 1
- 150000004692 metal hydroxides Chemical class 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Details Of Rigid Or Semi-Rigid Containers (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica la cual es útil para enfermedades neurodegenerativas, la cual comprende de aproximadamente 1 a aproximadamente 5 equivalentes de un ión metálico básico tomando como referencia 1 equivalente de ácido (2R)-2-propiloctanoico o una sal del mismo, el cual se suministra a partir de una sal metálica de ácido débil o un hidróxido metálico, y opcionalmente comprende adicionalmente un aditivo. La composición farmacéutica de la presente invención tiene un pH el cual es adecuado para administración intravenosa, es resistente a fluctuaciones del pH y no se enturbia cuando se disuelve en una infusión, y una inyección y similar se puede preparar a partir de ahí usando cualquier líquido disolvente y/o líquido de dilución.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003345124 | 2003-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066477A true ECSP066477A (es) | 2007-03-29 |
Family
ID=34419441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006477A ECSP066477A (es) | 2003-10-03 | 2006-04-03 | Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8053599B2 (es) |
| EP (1) | EP1669065B1 (es) |
| JP (1) | JP4715515B2 (es) |
| KR (1) | KR101144553B1 (es) |
| CN (1) | CN1889942B (es) |
| AU (1) | AU2004277826B2 (es) |
| BR (1) | BRPI0415001A (es) |
| CA (1) | CA2540670A1 (es) |
| EC (1) | ECSP066477A (es) |
| ES (1) | ES2390055T3 (es) |
| IL (1) | IL174655A0 (es) |
| IS (1) | IS8430A (es) |
| MA (1) | MA28142A1 (es) |
| MX (1) | MXPA06003533A (es) |
| NO (1) | NO20061460L (es) |
| NZ (1) | NZ546231A (es) |
| RU (1) | RU2388467C2 (es) |
| SG (1) | SG146687A1 (es) |
| TW (1) | TW200519080A (es) |
| WO (1) | WO2005032536A1 (es) |
| ZA (1) | ZA200602690B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200613009A (en) * | 2004-06-11 | 2006-05-01 | Ono Pharmaceutical Co | Capsule having chewing stability |
| TWI462745B (zh) * | 2005-04-28 | 2014-12-01 | Takeda Pharmaceutical | 安定的乳化組成物 |
| JP5541845B2 (ja) * | 2008-03-28 | 2014-07-09 | Ｊｃｒファーマ株式会社 | アトピー性皮膚炎治療剤 |
| CA2742659C (en) * | 2008-11-04 | 2016-09-27 | Aska Pharmaceutical Co., Ltd. | Aqueous composition containing follicle-stimulating hormone |
| EP2349309A4 (en) | 2008-11-20 | 2014-01-08 | Teikoku Pharma Usa Inc | FORMULATIONS OF PYRAZOLE DERIVATIVES |
| JP5759804B2 (ja) * | 2011-06-27 | 2015-08-05 | 富士フイルム株式会社 | 容器詰製剤 |
| JP2018052861A (ja) * | 2016-09-29 | 2018-04-05 | ノーベルファーマ株式会社 | ホスフェニトインナトリウム注射剤 |
| WO2020128928A1 (en) * | 2018-12-19 | 2020-06-25 | Jafari Javid Mihan | A formulation for treatment of neurodegenerative and demyelinating and neuropathic disorders and a method for preparation thereof |
| CN110441421B (zh) * | 2019-08-02 | 2022-09-09 | 聊城高新生物技术有限公司 | 一种高效液相色谱法测定恩他卡朋片溶出度的方法 |
| CN112180095B (zh) * | 2020-06-04 | 2023-10-13 | 三诺生物传感股份有限公司 | 一种心脑血管和糖尿病相关四高指标复合质控品及其制备方法 |
| IT202000015895A1 (it) * | 2020-07-27 | 2022-01-27 | Univ Cattolica Del Sacro Cuore | L’impiego di acido arundico nella terapia della sclerosi multipla |
| PH12023553209A1 (en) * | 2021-05-26 | 2024-02-19 | Daewoong Pharmaceutical Co Ltd | Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine |
| CN113341019A (zh) * | 2021-06-09 | 2021-09-03 | 江西省药品检验检测研究院 | 一种乳酸左氧氟沙星氯化钠注射液中依地酸盐的分析方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69408373T2 (de) * | 1993-06-01 | 1998-07-16 | Ono Pharmaceutical Co | Pentansäurederivate |
| JPH0782146A (ja) * | 1993-07-23 | 1995-03-28 | Sagami Chem Res Center | 抗痴呆薬 |
| JPH07285911A (ja) | 1994-04-20 | 1995-10-31 | New Japan Chem Co Ltd | 脂肪族モノカルボン酸組成物 |
| JPH0853351A (ja) * | 1994-08-11 | 1996-02-27 | Sagami Chem Res Center | 酵素阻害剤、血管新生抑制剤、および癌転移抑制剤 |
| JP3032447B2 (ja) * | 1995-04-24 | 2000-04-17 | 小野薬品工業株式会社 | 光学活性な２−プロピルオクタン酸の製造方法 |
| JP3084345B2 (ja) * | 1995-04-26 | 2000-09-04 | 小野薬品工業株式会社 | 光学活性な２−プロピルオクタン酸の製造方法 |
| JPH10298072A (ja) | 1997-04-17 | 1998-11-10 | Panacea Biotec Ltd | 非ステロイド性抗炎症剤の遷移金属錯体 |
| US6043223A (en) * | 1997-11-12 | 2000-03-28 | The Regents Of The University Of California | Enhanced opening of abnormal brain tissue capillaries |
| TWI268921B (en) * | 1999-02-18 | 2006-12-21 | Ono Pharmaceutical Co | A process for preparing (2R)-2-propyloctanoic acid |
| US6552082B2 (en) * | 2000-06-29 | 2003-04-22 | Ono Pharmaceutical Co., Ltd. | Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof |
| KR100759771B1 (ko) * | 2000-07-18 | 2007-10-04 | 오노 야꾸힝 고교 가부시키가이샤 | 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제 |
| JP4706950B2 (ja) * | 2000-07-18 | 2011-06-22 | 小野薬品工業株式会社 | アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤 |
| CA2453478A1 (en) * | 2001-07-18 | 2003-01-30 | Ono Pharmaceutical Co., Ltd. | Agent for treatment of cerebral ischemic diseases |
-
2004
- 2004-10-01 RU RU2006114835/15A patent/RU2388467C2/ru not_active IP Right Cessation
- 2004-10-01 CA CA002540670A patent/CA2540670A1/en not_active Abandoned
- 2004-10-01 NZ NZ546231A patent/NZ546231A/en unknown
- 2004-10-01 AU AU2004277826A patent/AU2004277826B2/en not_active Ceased
- 2004-10-01 WO PCT/JP2004/014892 patent/WO2005032536A1/ja not_active Ceased
- 2004-10-01 CN CN2004800361288A patent/CN1889942B/zh not_active Expired - Fee Related
- 2004-10-01 US US10/574,477 patent/US8053599B2/en not_active Expired - Fee Related
- 2004-10-01 TW TW093129802A patent/TW200519080A/zh unknown
- 2004-10-01 JP JP2005514507A patent/JP4715515B2/ja not_active Expired - Fee Related
- 2004-10-01 KR KR1020067008535A patent/KR101144553B1/ko not_active Expired - Fee Related
- 2004-10-01 MX MXPA06003533A patent/MXPA06003533A/es not_active Application Discontinuation
- 2004-10-01 EP EP04792177A patent/EP1669065B1/en not_active Expired - Lifetime
- 2004-10-01 BR BRPI0415001-5A patent/BRPI0415001A/pt not_active Application Discontinuation
- 2004-10-01 SG SG200807282-9A patent/SG146687A1/en unknown
- 2004-10-01 ES ES04792177T patent/ES2390055T3/es not_active Expired - Lifetime
-
2006
- 2006-03-30 IL IL174655A patent/IL174655A0/en unknown
- 2006-03-31 ZA ZA200602690A patent/ZA200602690B/en unknown
- 2006-03-31 NO NO20061460A patent/NO20061460L/no not_active Application Discontinuation
- 2006-04-03 EC EC2006006477A patent/ECSP066477A/es unknown
- 2006-04-26 IS IS8430A patent/IS8430A/is unknown
- 2006-05-02 MA MA28991A patent/MA28142A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP4715515B2 (ja) | 2011-07-06 |
| EP1669065A4 (en) | 2009-12-16 |
| ES2390055T3 (es) | 2012-11-06 |
| JPWO2005032536A1 (ja) | 2006-12-14 |
| US20070105956A1 (en) | 2007-05-10 |
| WO2005032536A1 (ja) | 2005-04-14 |
| AU2004277826A1 (en) | 2005-04-14 |
| CN1889942A (zh) | 2007-01-03 |
| BRPI0415001A (pt) | 2006-11-07 |
| AU2004277826B2 (en) | 2010-05-27 |
| KR101144553B1 (ko) | 2012-05-11 |
| NO20061460L (no) | 2006-07-03 |
| MXPA06003533A (es) | 2006-06-08 |
| EP1669065B1 (en) | 2012-07-18 |
| ZA200602690B (en) | 2007-07-25 |
| KR20060099525A (ko) | 2006-09-19 |
| RU2006114835A (ru) | 2007-11-20 |
| RU2388467C2 (ru) | 2010-05-10 |
| US8053599B2 (en) | 2011-11-08 |
| IL174655A0 (en) | 2006-08-20 |
| CA2540670A1 (en) | 2005-04-14 |
| IS8430A (is) | 2006-04-26 |
| CN1889942B (zh) | 2010-12-15 |
| MA28142A1 (fr) | 2006-09-01 |
| SG146687A1 (en) | 2008-10-30 |
| TW200519080A (en) | 2005-06-16 |
| EP1669065A1 (en) | 2006-06-14 |
| NZ546231A (en) | 2009-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP066477A (es) | Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo | |
| UA95488C2 (ru) | Концентрированный раствор метотрексата для подкожного введения | |
| AR109494A1 (es) | Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos | |
| BRPI0706676B8 (pt) | uso de uma solução aquosa com potencial de oxirredução | |
| CU23814A3 (es) | Emulsión intravenosa de butilftalida y aplicación de la misma | |
| EA200700389A1 (ru) | Стабильный при хранении инфузионный раствор дигидроптеридинонов | |
| AR107014A1 (es) | Formulación farmacéutica acuosa | |
| WO2009097443A3 (en) | Liquid formulations of compounds active at sulfonylurea receptors | |
| BR112019023981A2 (pt) | injeção de octreotida | |
| BRPI0418474A (pt) | solução aquosa parenteral estável | |
| ATE539761T1 (de) | Mittel für injektionszwecke mit einem antibiotikum und das mittel enthaltende lösung zur injektion | |
| CL2008001332A1 (es) | Uso de temozolomida para preparar un medicamento util para el tratamiento de un desorden proliferativo. | |
| BRPI0519209A2 (pt) | compostos orgçnicos | |
| ECSP066476A (es) | Preparación de una infusión que comprende ácido (2r)-2-propiloctanoico como ingrediente activo | |
| DE602005025638D1 (de) | Kolloidale insluinformulierung mit langzeitwirkung und deren herstellung | |
| DOP2005000053A (es) | Composicion farmaceutica que comprende acido (2r)-2-propilactanoico como un ingrediente activo | |
| AR049015A1 (es) | Composicion farmaceutica que comprende acido (2r)-2-propiloctanoico como un ingrediente activo | |
| BR112017012975A2 (pt) | formulações injetáveis de paracetamol | |
| UA93365C2 (ru) | Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты) | |
| KR20060061351A (ko) | 글리시리진 고농도 제제 | |
| CO6270205A2 (es) | Formulacion que contiene un compuesto inhibidor de quinasa dependiente de ciclina y metodo para tratar tumores utilizando el mismo | |
| PE20220932A1 (es) | Composicion farmaceutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso | |
| DOP2005000052A (es) | Preparacion de infusión que comprende acido (2r)-2-propilactanoico como un ingrediente activo | |
| RU2016144342A (ru) | Стабильные композиции нейроактивных пептидов | |
| UA84578C2 (ru) | Лекарственное средство, содержащее (2r)-2-пропилоктановую кислоту в качестве активного ингредиента |